Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yondelis in Advanced Prostate Carcinoma
NCT00072670Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2004
- Primary completion
- Sep 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trabectedin in prostate cancer (PCa) (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Percentage of Participants Achieving Prostate-Specific Antigen (PSA) Response. Started Jan 2004; status: completed.
02
Drugs
trabectedin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00072670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072670.